ACSM3 suppresses proliferation and induces apoptosis and cell cycle arrest in acute myeloid leukemia cells via the regulation of IGF2BP2

Zheng,Xin; Wu,Jinjun; Song,Linlan; Huang,Bo

doi:10.3892/etm.2023.11876

ACSM3 suppresses proliferation and induces apoptosis and cell cycle arrest in acute myeloid leukemia cells via the regulation of IGF2BP2

Authors:
- Xin Zheng
- Jinjun Wu
- Linlan Song
- Bo Huang
View Affiliations

Affiliations: Department of Clinical Laboratory, Jianghan Oilfield General Hospital of Changjiang University, Qianjiang, Hubei 433124, P.R. China, Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Clinical Laboratory, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710003, P.R. China
Published online on: March 8, 2023 https://doi.org/10.3892/etm.2023.11876
Article Number: 177
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acyl‑CoA medium‑chain synthetase‑3 (ACSM3) has been reported to be involved in the malignant progression of multiple types of human cancer. Nevertheless, the role of ACSM3 in acute myeloid leukemia (AML) and its exact mechanism of action are as yet undefined. In the present study, the expression levels of ACSM3 and IGF2 mRNA‑binding protein 2 (IGF2BP2) were evaluated using the Gene Expression Profiling Interactive Analysis database and AML cells. The Cell Counting Kit‑8 assay and 5‑ethynyl‑2'‑deoxyuridine staining were employed for the estimation of the cell proliferative activity. Induction of apoptosis and the assessment of the cell cycle were measured using flow cytometry and western blotting, respectively. The interaction of ACSM3 with IGF2BP2 was confirmed using an RNA immunoprecipitation assay. mRNA stabilization of ACSM3 following actinomycin D treatment was evaluated using reverse transcription‑quantitative PCR analysis. The data indicated that the expression levels of ACSM3 were significantly downregulated, whereas those of IGF2BP2 were upregulated in tissues and AML cells. Downregulation of ACSM3 expression was closely associated with poor overall survival of patients with AML. ACSM3 overexpression repressed cell proliferative activity and induced apoptosis and cell cycle arrest. IGF2BP2 downregulated ACSM3 expression by reducing the stability of ACSM3 mRNA. In addition, IGF2BP2 overexpression counteracted the effects of ACSM3 overexpression noted on proliferation, induction of apoptosis and cell cycle arrest of HL‑60 cells. In conclusion, ACSM3 repressed the cell proliferative activity and facilitated induction of apoptosis and cell cycle arrest in AML cells by modulating the expression of IGF2BP2.

View Figures

View References

1	Cammarata-Scalisi F, Girardi K, Strocchio L, Merli P, Garret-Bernardin A, Galeotti A, Magliarditi F, Inserra A and Callea M: Oral manifestations and complications in childhood acute myeloid leukemia. Cancers (Basel). 12(1634)2020.PubMed/NCBI View Article : Google Scholar
2	Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki T, Deguchi T, et al: A risk-stratified therapy for infants with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial. Blood. 136:1813–1823. 2020.PubMed/NCBI View Article : Google Scholar
3	Prada-Arismendy J, Arroyave JC and Röthlisberger S: Molecular biomarkers in acute myeloid leukemia. Blood Rev. 31:63–76. 2017.PubMed/NCBI View Article : Google Scholar
4	Medinger M, Heim D, Halter JP, Lengerke C and Passweg JR: Diagnosis and therapy of acute myeloid leukemia. Ther Umsch. 76:481–486. 2019.PubMed/NCBI View Article : Google Scholar : (In German).
5	Chopra M and Bohlander SK: The cell of origin and the leukemia stem cell in acute myeloid leukemia. Genes Chromosomes Cancer. 58:850–858. 2019.PubMed/NCBI View Article : Google Scholar
6	Medeiros BC, Chan SM, Daver NG, Jonas BA and Pollyea DA: Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 94:803–811. 2019.PubMed/NCBI View Article : Google Scholar
7	Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, et al: Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 17:721–749. 2019.PubMed/NCBI View Article : Google Scholar
8	Kantarjian H: Acute myeloid leukemia-major progress over four decades and glimpses into the future. Am J Hematol. 91:131–145. 2016.PubMed/NCBI View Article : Google Scholar
9	Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, et al: Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 93:1074–1081. 2018.PubMed/NCBI View Article : Google Scholar
10	Zhang L, Sun W, Ren W, Zhang J and Xu G: Predicting panel of metabolism and immune-related genes for the prognosis of human ovarian cancer. Front Cell Dev Biol. 9(690542)2021.PubMed/NCBI View Article : Google Scholar
11	Junková K, Mirchi LF, Chylíková B, Janků M, Šilhavý J, Hüttl M, Marková I, Miklánková D, Včelák J, Malínská H, et al: Hepatic transcriptome profiling reveals lack of Acsm3 expression in polydactylous rats with high-fat diet-induced hypertriglyceridemia and visceral fat accumulation. Nutrients. 13(1462)2021.PubMed/NCBI View Article : Google Scholar
12	Bi WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, Brewster R, Dunn GP, Al-Mefty O, Alexander BM, et al: Genomic landscape of intracranial meningiomas. J Neurosurg. 125:525–535. 2016.PubMed/NCBI View Article : Google Scholar
13	Wang D, Liu CD, Li HF, Tian ML, Pan JQ, Shu G, Jiang QY, Yin YL and Zhang L: LSD1 mediates microbial metabolite butyrate-induced thermogenesis in brown and white adipose tissue. Metabolism. 102(154011)2020.PubMed/NCBI View Article : Google Scholar
14	Yang X, Wu G, Zhang Q, Chen X, Li J, Han Q, Yang L, Wang C, Huang M, Li Y, et al: ACSM3 suppresses the pathogenesis of high-grade serous ovarian carcinoma via promoting AMPK activity. Cell Oncol (Dordr). 45:151–161. 2022.PubMed/NCBI View Article : Google Scholar
15	Gopal R, Selvarasu K, Pandian PP and Ganesan K: Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression. Cell Oncol (Dordr). 40:219–233. 2017.PubMed/NCBI View Article : Google Scholar
16	Yan L, He Z, Li W, Liu N and Gao S: The Overexpression of Acyl-CoA Medium-Chain Synthetase-3 (ACSM3) Suppresses the Ovarian Cancer Progression via the Inhibition of Integrin β1/AKT Signaling Pathway. Front Oncol. 11(644840)2021.PubMed/NCBI View Article : Google Scholar
17	Ruan HY, Yang C, Tao XM, He J, Wang T, Wang H, Wang C, Jin GZ, Jin HJ and Qin WX: Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Am J Cancer Res. 7:543–553. 2017.PubMed/NCBI
18	Hu X, Peng WX, Zhou H, Jiang J, Zhou X, Huang D, Mo YY and Yang L: IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. Cell Death Differ. 27:1782–1794. 2020.PubMed/NCBI View Article : Google Scholar
19	Cui J, Tian J, Wang W, He T, Li X, Gu C, Wang L, Wu J and Shang A: IGF2BP2 promotes the progression of colorectal cancer through a YAP-dependent mechanism. Cancer Sci. 112:4087–4099. 2021.PubMed/NCBI View Article : Google Scholar
20	Xu X, Yu Y, Zong K, Lv P and Gu Y: Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 38(497)2019.PubMed/NCBI View Article : Google Scholar
21	He X, Li W, Liang X, Zhu X, Zhang L, Huang Y, Yu T, Li S and Chen Z: IGF2BP2 overexpression indicates poor survival in patients with acute myelocytic leukemia. Cell Physiol Biochem. 51:1945–1956. 2018.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Swaminathan M and Wang ES: Novel therapies for AML: A round-up for clinicians. Expert Rev Clin Pharmacol. 13:1389–1400. 2020.PubMed/NCBI View Article : Google Scholar
24	Zhao Z, Zhan Y, Jing L and Zhai H: KLF10 upregulates ACSM3 via the PI3K/Akt signaling pathway to inhibit the malignant progression of melanoma. Oncol Lett. 23(175)2022.PubMed/NCBI View Article : Google Scholar
25	Shu C, Zheng X, Wuhafu A, Cicka D, Doyle S, Niu Q, Fan D, Qian K, Ivanov AA, Du Y, et al: Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. Acta Pharmacol Sin. 43:2419–2428. 2022.PubMed/NCBI View Article : Google Scholar
26	Zhu Z, Wang D and Shen Y: Loss of ACSM3 confers worsened prognosis and immune exclusion to cutaneous melanoma. J Cancer. 11:6582–6590. 2020.PubMed/NCBI View Article : Google Scholar
27	An Y and Duan H: Acyl-CoA medium-chain synthetase-3 promotes chemosensitivity of ovarian cancer through the inhibition of PI3K/AKT signaling pathway. Research Square. 2021.
28	Fujii Y, Kishi Y and Gotoh Y: IMP2 regulates differentiation potentials of mouse neocortical neural precursor cells. Genes Cells. 18:79–89. 2013.PubMed/NCBI View Article : Google Scholar
29	Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, Shavlakadze T, Eash JK, Scaramozza A, Goddeeris MM, et al: An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. Dev Cell. 23:1176–1188. 2012.PubMed/NCBI View Article : Google Scholar
30	Boudoukha S, Cuvellier S and Polesskaya A: Role of the RNA-binding protein IMP-2 in muscle cell motility. Mol Cell Biol. 30:5710–5725. 2010.PubMed/NCBI View Article : Google Scholar
31	Barghash A, Helms V and Kessler SM: Overexpression of IGF2 mRNA-binding protein 2 (IMP2/p62) as a feature of basal-like breast cancer correlates with short survival. Scand J Immunol. 82:142–143. 2015.PubMed/NCBI View Article : Google Scholar
32	Barghash A, Golob-Schwarzl N, Helms V, Haybaeck J and Kessler SM: Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma. Oncotarget. 7:49743–49750. 2016.PubMed/NCBI View Article : Google Scholar
33	Huang GW, Chen QQ, Ma CC, Xie LH and Gu J: linc01305 promotes metastasis and proliferation of esophageal squamous cell carcinoma through interacting with IGF2BP2 and IGF2BP3 to stabilize HTR3A mRNA. Int J Biochem Cell Biol. 136(106015)2021.PubMed/NCBI View Article : Google Scholar
34	Shen H, Zhu H, Chen Y, Shen Z, Qiu W, Qian C and Zhang J: ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression. Cell Death Dis. 12(349)2021.PubMed/NCBI View Article : Google Scholar